ARUK 2023 | The reality of implementing an Alzheimer’s disease ‘blood test’ in clinical practice

Michael Schöll, PhD, University of Gothenburg, Gothenburg, Sweden, shares his thoughts on the challenges in implementing an Alzheimer’s disease ‘blood test’ in clinical practice. Given the lack of treatment options available, the consequences of divulging such information to patients must be considered. Systems must be in place to guide individuals on the meaning of their results. Prof. Schöll also notes the influence of health economics, with the cost of blood biomarker testing versus the money saved by reducing false positive diagnoses likely to come into play. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.